Optimizing Titer And Use Of A Specific Enzyme For Generating A Fully Processed Antibody
Summary: Complex biopharmaceutical proteins in development are becoming more and more the norm with the advent of new antibody formats, unique VLP structures and biopharmaceutical proteins that need additional processing. Producing multi subunit molecules or processing proteins in the correct proportions to obtain maximum titer and biopharmaceutical quality can be difficult using traditional cell-line development technologies. The authors outline cell development and process scale-up for an antibody program in which the antibody requires additional processing by a site-specific enzyme for correct functionality. The article was originally published in BioPharm International.